| Project/Area Number |
08670640
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
AKITA Hirotoshi Hokkaido Univ., Medical Hospital., Lecturer, 医学部・附属病院, 講師 (70222528)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Project Status |
Completed (Fiscal Year 1997)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1997: ¥1,200,000 (Direct Cost: ¥1,200,000)
Fiscal Year 1996: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | Lung Cancer / Gene Expression / Antisense / Retinoic Acid |
|---|
| Research Abstract |
The overexpression of c-myc frequently accmpanies the relapse of small cell lung cancers (SCLCs) and contributes to the poor prognosis of patients with SCLVs. In this tudy, We investigated whether c-myc antisense oligodeoxynucleoside phosphorothioate (OPT) used in combination with all-trans-retinoic acid (RA) could be an experimental therapeutic tool against c-myc in a SCLC cell lime, NCI-H82, overexpressing c-myc with amplification of this gene. A c-myc antisense OPT covering the translational initiation site of c-myc mRNA decreased c-myc expression and inhibited cell growth. AII-trans RA also down-regulated c-myc expression as well as cell growth, as was previously reported. A combination of this antisenes DNA with all-trans-RA exhibited a enhanced reduction of c-myc expression over either agent given alone. Furthermore, this combination showed a greater inhibition of cell growth through c-myc down-regulation than either agent alone.
These data suggest that c-myc antisense DNA in combination with RA may represent an attractive modality of gene regulation-based therapy of SCLCs in future, although further efforts are needed for the more potent down-regulation of c-myc.
|
